A phase IV study of the effectiveness of quetiapine extended release 600mg once a day to control the symptoms of manic phase of bipolar disorder

Trial Profile

A phase IV study of the effectiveness of quetiapine extended release 600mg once a day to control the symptoms of manic phase of bipolar disorder

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jul 2012

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Bipolar disorders
  • Focus Therapeutic Use
  • Acronyms EMMY
  • Sponsors AstraZeneca
  • Most Recent Events

    • 09 Dec 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
    • 09 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Aug 2008 Actual start date added (May 2008) as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top